International Cardio Corporation Achieves First Human Use of Its Noninvasive HIFU Treatment for Peripheral Vascular Disease

sourced

Categories

Via News Release

Image result for International Cardio CorporationMINNEAPOLIS–(BUSINESS WIRE)–International Cardio Corporation (ICC) announced today that it has achieved the first human use milestone of its HIFU Synthesizer™, a therapeutic ultrasound system designed to noninvasively treat vulnerable and occlusive plaques in peripheral arteries. The first of a fifteen patient Safety Study in the Netherlands, this achievement supports the company’s core objectives to reduce stroke mortality and improve the quality of life for those suffering from peripheral vascular disease (PVD).

Sponsors